Oculis’ (OCS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Oculis (NASDAQ:OCS) in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has a $30.00 price objective on the stock.

Oculis Stock Up 2.8 %

OCS opened at $16.26 on Wednesday. The stock has a market capitalization of $658.60 million, a price-to-earnings ratio of -9.13 and a beta of 0.30. The firm has a 50 day moving average price of $12.81 and a 200-day moving average price of $12.18. Oculis has a twelve month low of $9.05 and a twelve month high of $16.70. The company has a quick ratio of 5.27, a current ratio of 5.27 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. The firm had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. Equities research analysts forecast that Oculis will post -2.19 earnings per share for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.